TGTX 📈 TG Therapeutics - Overview

TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company that has established itself as a key player in the development and commercialization of novel treatments for B-cell mediated diseases. With a focus on addressing the complex needs of patients in the United States and internationally, the company has developed a robust portfolio of therapies, including BRIUMVI, an anti-CD20 monoclonal antibody designed to treat adult patients with relapsing forms of multiple sclerosis, encompassing clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

The company's development pipeline is characterized by a diverse range of investigational therapies, including Umbralisib, an oral inhibitor of PI3K-delta, which has shown promise in the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma. Additionally, TG-1701, an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor, has demonstrated selectivity to BTK in vitro kinase screening, positioning it as a potential treatment option for various B-cell mediated diseases. Furthermore, TG-1801, a bispecific CD47 and CD19 antibody, is another notable candidate in the company's pipeline, offering a unique approach to targeting cancer cells.

TG Therapeutics, Inc. has also established a network of strategic partnerships and collaborations, including license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, and Ildong Pharmaceutical Co. Ltd., among others, to drive the development and commercialization of its therapies, such as Umbralisib. The company has also entered into a collaboration agreement with Checkpoint Therapeutics, Inc. to advance the development of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. With a strong foundation in research and development, TG Therapeutics, Inc. is well-positioned to continue delivering innovative treatments for patients with B-cell mediated diseases.

Founded in 1993 and headquartered in Morrisville, North Carolina, TG Therapeutics, Inc. has evolved into a leading biopharmaceutical company, with a web presence at https://www.tgtherapeutics.com. The company's common stock is listed under the ISIN US88322Q1085 and is classified under the GICS Sub Industry: Biotechnology, reflecting its focus on developing and commercializing innovative biotechnology products. As a commercial-stage company, TG Therapeutics, Inc. is committed to delivering value to its stakeholders, including patients, healthcare providers, and investors, by advancing its pipeline of novel therapies and establishing itself as a trusted partner in the biopharmaceutical industry.